Hero image with Pittsburgh background https://pittplusme.org/study/2347

NO IN-PERSON VISITS
STUDY BASICS

Are you 18 or over with a gastroenteropancreatic (GEP) or lung neuroendocrine tumor (NET)? You may be eligible to participate in a research study based on your NET diagnosis. Compensation is provided.


STUDY PURPOSE

NETs are typically slow growing in nature with prolonged survival and significant symptom burdens, however few studies have examined quality of life impacts. This study is being conducted for several reasons: to describe the symptoms and quality of life with different NET treatments, to learn what patient and tumor factors influence the order that treatments are given, and to learn whether treatment order affects quality of life, symptoms, and survival. This study will also help others conduct research on NETs and other rare diseases. 


COULD THIS STUDY BE RIGHT FOR YOU?
  • Ages 18 and older 
  • First diagnosed with GEP-NET or lung NET between 01/01/2018 and 9/30/2024 

WHAT PARTICIPANTS CAN EXPECT

This study involves taking four online (or paper) surveys spaced six months apart. Each survey asks questions about your health and health care, and many questions are related to your neuroendocrine tumor. The surveys focuses on patient-reported outcomes, including questions on quality of life, treatment decisions, and experiences with cancer care.The first survey will take about 40 minutes to complete; the other three surveys will take about 20 minutes each to complete. Information from your medical record will be collected for about 36 months from the time of study enrollment. 


IRB: STUDY22010006
- Neuroendocrine Tumors - Patient Reported Outcomes (NET-PRO)

PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit https://pittplusme.org/study/2347 and click on "I'm Interested" or call 1-866-438-8230.


LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


David Geller

Dr. Geller is the Richard L. Simmons Professor of Surgery at the University of Pittsburgh School of Medicine. He serves as Chief of the Division of Hepatobiliary and Pancreatic Surgery, and Director of the UPMC Liver Cancer Center. Clinically, he specializes in laparoscopic liver resection surgery. His research interests include molecular mechanisms of hepatic ischemia/ reperfusion injury, and liver cancer cell biology. Dr. Geller is a member of many professional societies including the Society of University Surgeons (President 2009-2010), ASA, ASTS, SSO, AHPBA, IHPBA, ILLS (President 2021-2023), SAGES, SSAT, and ASCI. Dr. Geller has published 400 scientific papers and chapters, and has presented at more than 450 meetings or seminars. He has active research funding from the NIH.